Clik here to view.
Mustang Bio Announces Additional Clinical Data on MB-107
Mustang Bio (NASDAQ:MBIO) has announced updated Phase 1/2 clinical date for MB-107 was presented at the National Institutes of Health at the 61st American Society of Hematology (ASH) meeting. As quoted...
View ArticleClik here to view.
5 Top Medical Device News Stories of 2019
Throughout the course of 2019, investors in the medical device space were interested in a variety of stories on the growth and catalysts available to companies in this sector. From US Food and Drug...
View ArticleClik here to view.
5 Top Genetics News Stories of 2019
The genetics industry is catching the attention of investors and the life sciences sector as a whole, and it is shaping the way other industries within the space are operating. From stem cell research,...
View ArticleClik here to view.
MacroGenics Presents Results from SOPHIA Study
MacroGenics (NASDAQ:MGNX) has announced updated results from its Phase 3 SOPHIA study in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER@-targeted...
View ArticleClik here to view.
Avenue Therapeutics Submits New Drug Application for IV Tramadol
Avenue Therapeutics (NASDAQ:ATXI) has announced it has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for IV tramadol to manage moderate to moderately severe pain...
View ArticleClik here to view.
Dare Biosciences and FDA Align on Phase 2b Study Design of Sildenafil
Dare Bioscience (NASDAQ:DARE) has announced that it and the US Food and Drug Administration have reached an agreement on the patient reported outcome (PRO) instruments to be used in a Phase 2b clinical...
View ArticleClik here to view.
BioXcel Therapeutics to Expand BXCL701 Study
BioXcel Therapeutics (NASDAQ:BTAI) has announced that it will advance its clinical evaluation of BXCL801 into multiple advanced solid tumors. As quoted in the press release: BXCL701 is an orally...
View ArticleClik here to view.
Biotech Trends 2019: M&A Slows, CNS Therapies Make Headlines
This year was another crucial one for biotech thanks in large part to initial public offerings (IPOs), merger and acquisition (M&A) activity and niche therapeutic areas garnering attention. During...
View ArticleClik here to view.
5 Top NASDAQ Biotech and Pharma Stocks: Neoleukin Up 98 Percent
The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) had a turbulent week, starting at 3,788.38 points on Monday’s (December 9) open and reaching a five day high of 3,808.32 points on Friday (December 13)...
View ArticleClik here to view.
Abeona Therapeutics to Initiate Phase 3 Clinical Trial of B-101
Abeona Therapeutics (NASDAQ:ABEO) has announced that the US Food and Drug Administration (FDA) has cleared the company to initiate a Phase 3 clinical trial evaluating EB-101 to treat recessive...
View Article
